title: The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation.
abstract: The bcr-abl chimeric messenger RNA is frequently detected in chronic myeloid leukemia (CML) patients after bone marrow transplantation. It was previously reported that the relapse risk of bcr-abl detection 6 to 12 months after transplantation was greater than 40%. This risk decreased as the time between transplantation and detection increased. To further define the relapse risk associated with bcr-abl molecular detection in "late" CML survivors, 379 consecutive CML patients alive at 18 months after transplantation or later were studied. Ninety of 379 patients (24%) had at least one positive bcr-abl test 18 months after transplantation or later; 13 of 90 bcr-abl-positive patients (14%) and 3 of 289 bcr-abl-negative patients (1.0%) relapsed. The median time from bcr-abl detection to relapse was 916 days (range, 251-2654 days). The hazard ratio of relapse associated with bcr-abl detection was 19.2 (P <.0001). The stage of disease, chronic graft-versus-host disease, and the donor type did not alter the association between bcr-abl and relapse. Quantification of bcr-abl was performed on 344 samples from 85 bcr-abl-positive patients by means of a real-time quantitative reverse transcriptase-polymerase chain reaction assay. The median bcr-abl change of patients who relapsed was significantly greater than those that remained in remission (P =.002). The median bcr-abl level at relapse was 40 443 bcr-abl copies per microg RNA (range, 960-299 552). Of 73 bcr-abl-positive patients who failed to relapse, 69% had only one positive test at a median of 24 copies bcr-abl per microg RNA. The detection of bcr-abl is common following transplantation. The prognostic significance of a qualitative bcr-abl can be refined by quantitative assays and thus may target patients who would benefit from early intervention.
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, the University of Washington School of Medicine, Seattle, WA, USA. jradich@fhcrc.org
authors.forename: J P
authors.initials: JP
authors.lastname: Radich
authors.forename: T
authors.initials: T
authors.lastname: Gooley
authors.forename: E
authors.initials: E
authors.lastname: Bryant
authors.forename: T
authors.initials: T
authors.lastname: Chauncey
authors.forename: R
authors.initials: R
authors.lastname: Clift
authors.forename: L
authors.initials: L
authors.lastname: Beppu
authors.forename: S
authors.initials: S
authors.lastname: Edmands
authors.forename: M E
authors.initials: ME
authors.lastname: Flowers
authors.forename: K
authors.initials: K
authors.lastname: Kerkof
authors.forename: R
authors.initials: R
authors.lastname: Nelson
authors.forename: F R
authors.initials: FR
authors.lastname: Appelbaum
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D007700:Kinetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000378:metabolism / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012334:RNA, Neoplasm / Q000096:biosynthesis; D012307:Risk Factors
chemical_list: D012334:RNA, Neoplasm; D016044:Fusion Proteins, bcr-abl